RANCHO CUCAMONGA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2017.
First Quarter Highlights
- Net revenues of $56.7 million for the first quarter
- GAAP net income of $0.9 million, or $0.02 per diluted share, for the first quarter
- Adjusted non-GAAP net income of $4.5 million, or $0.09 per diluted share, for the first quarter
Dr. Jack Zhang, Amphastar’s CEO, commented: “We continue to execute on our pipeline, having filed four ANDAs in the past two quarters. We will use our extensive research and development capabilities to further expand our pipeline.”
